TMX Newsfile Health News Releases

Optimind Pharma Announces Adoption of Semi-Annual Reporting

Fri, 24 Jul 2026 09:04:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily...

TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET

Fri, 24 Jul 2026 07:35:00 -0400

Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended June 30, 2026,...

One Hemp Welcomes Bipartisan Push for Common-Sense Hemp Regulation

Thu, 23 Jul 2026 08:08:00 -0400

Washington, D.C.--(Newsfile Corp. - July 23, 2026) - ONE HEMP, a national coalition representing responsible hemp businesses and advocates, today welcomed the introduction of the bipartisan Lawful Hemp Protection Act, introduced by Reps. Andy Barr (R-KY) and Angie Craig (D-MN), calling it a significant step toward a responsible, federally regulated hemp marketplace that protects consumers without dismantling a vital American industry.The bill would establish federal standards for hemp products,...

Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Thu, 23 Jul 2026 01:01:00 -0400

Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments Investor call today at 3 pm CET Dublin, Ireland--(Newsfile Corp. -...

Hemostemix Grants Stock Options

Wed, 22 Jul 2026 16:50:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous...

Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada

Wed, 22 Jul 2026 10:00:00 -0400

Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its technology for the early detection of breast cancer in breath for women with dense breasts, as an adjunct to mammography.The study is...

MNDR Wins 2026 Technology for Good Award, Featuring Aiko in Its AI Intelligent Healthcare Ecosystem

Wed, 22 Jul 2026 08:38:00 -0400

Singapore, Singapore--(Newsfile Corp. - July 22, 2026) - Mobile-health Network Solutions Inc. (NASDAQ: MNDR) ("MNDR"), an AI-powered intelligent healthcare ecosystem, today announced it has been awarded the 2026 Technology for Good Distinction Award, following its recognition in 2025.This year's award highlights MNDR's AI Intelligent Healthcare Ecosystem, anchored by Aiko — the Agentic Patient Companion. Powered by MNDR's proprietary PhiGPT clinical AI engine, Aiko transforms healthcare from...

Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Commercial Progress, Additional NIRLAB Device Sale, and Rapid Detection Strip Expansion

Wed, 22 Jul 2026 07:08:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 22, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to provide shareholders with an update across several areas of its business.New OTCQB Trading SymbolThe Company's common shares commenced trading on the OTCQB under the new ticker symbol "ATVHF," effective as of market open on July 17, 2026, replacing the Company's prior symbol "SSPLF." The change does not affect the Company's share...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400